SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
AFFYMETRIX (AFFX)
An SI Board Since April 1996
Posts SubjectMarks Bans Symbol
1728 86 0 AFFX
Emcee:  Jed Davidow Type:  Unmoderated
Affymetrix is a spin-off of Affymax. Does anyone have any knowledge
of this company? (I will also post this to the IPO forum)

-jed
(Sorry, no word wrap)

FOR IMMEDIATE RELEASE
FOR FURTHER INFORMATION CONTACT:

Kenneth J. Nussbacher
Executive Vice President and Chief Financial Officer
Affymetrix, Inc.
3380 Central Expressway
Santa Clara, CA 95051
(408) 522-6000

AFFYMETRIX, INC. FILES REGISTRATION
STATEMENT FOR INITIAL PUBLIC OFFERING

Santa Clara, CA, April 15, 1996. Affymetrix, Inc., ("Affymetrix" or the
"Company"; proposed Nasdaq National Market Symbol: AFFX) announced today that i
t has filed a registration statement with the Securities and Exchange Commission
for an initial public offering of 5,000,000 shares of Common Stock. The offeri
ng price is expected to be between $11.00 and $13.00 per share. All of the shar
es are being sold by Affymetrix. The Company will have 21,166,266 shares of Com
mon Stock outstanding after the offering. The offering will be managed by Robert
son, Stephens & Company LLC, CS First Boston Corporation and Montgomery Securiti
es.

Affymetrix has developed and intends to establish its GeneChip8 system a
s the platform of choice for acquiring, analyzing and managing complex genetic i
nformation in order to improve the diagnosis, monitoring and treatment of diseas
e. The Company's GeneChip8 system consists of disposable DNA probe arrays contai
ning gene sequences on a chip, instruments to process the probe arrays, and soft
ware to analyze and manage genetic information. The Company is commencing commer
cial sales of the GeneChip8 system and an HIV probe array for research use in Ap
ril 1996.

The net proceeds to the Company from the offering will be used for produ
ct development, manufacturing scale-up, research, sales and marketing and capita
l equipment, as well as for working capital and other general corporate purposes
.

A registration statement relating to these securities has been filed wit
h the Securities and Exchange Commission but has not yet become effective. The s
ecurities may not be sold nor may offers to buy be accepted prior to the time th
e registration statement becomes effective. This press release shall not consti
tute an offer to sell or a solicitation of an offer to buy nor shall there be an
y sale of these securities in any state or jurisdiction in which such offer, sol
icitation or sale would be unlawful prior to registration or qualification under
the securities laws of any such state or jurisdiction.

Copies of the preliminary prospectus relating to the offering may be obt
ained from Robertson, Stephens & Company LLC, 555 California Street, Suite 2600,
San Francisco, CA 94104, (415) 781-9700; CS First Boston Corporation, 55 East 5
2nd Street, New York, NY 10055, (212) 909-2000; or Montgomery Securities, 600 Mo
ntgomery Street, San Francisco, CA 94111, (415) 627-2000.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1728Whoops. Sorry! SteveKsteve kammerer-1/6/2013
1727>>How come with all that's happened with AFFY there isn't ANY actitnsaf-1/4/2013
1726How come with all that's happened with AFFY there isn't ANY activity anysteve kammerer11/3/2013
1725two interesting headlines on AFFX (notice the dates) ...........................Jon Koplik-10/22/2009
1724Affymetrix Misses Revenue Again And Again (AFFX) October 16, 2008 | By Eric Fox tnsaf-10/16/2008
1723<b>Affymetrix in new patents row</b> Published online 23 July 2008 idos-7/24/2008
1722Affymetrix Lowers Full-Year Outlook Monday April 14, 4:38 pm ET Affymetrix Expectnsaf-4/14/2008
1721The United States Patent and Trademark Office Orders the Re-Examination of Two Ptnsaf-12/21/2007
1720Affymetrix to Acquire USB Corporation Tuesday December 18, 8:00 am ET USB's tnsaf-12/18/2007
1719Affymetrix to Offer $250M of Notes <i>Severe lack of details</i> Ttnsaf-11/13/2007
1718Affymetrix Files Second Wave of Patent Infringement Lawsuits Against Illumina intnsaf-10/24/2007
1717Affymetrix Reports Third Quarter 2007 Results Wednesday October 24, 4:00 pm ET tnsaf-10/24/2007
1716German National Genome Research Network to Analyze More Than 17,000 DNA Samples tnsaf-4/26/2007
1715Illumina found to infringe 5 Affymetrix patents LOS ANGELES, March 13 (Reuters) tnsaf-3/14/2007
1714Affymetrix Expresses Profits By Ralph Casale (MF) February 12, 2007 2006 was a bob zagorin-2/12/2007
1713Affymetrix Up on 3Q Results, Upgrade Thursday October 26, 12:09 pm ET Affymetrixtnsaf-10/27/2006
1712Affymetrix Signs First Translational Medicine Agreement in China Monday Septembetnsaf-9/18/2006
1711Triggering Events That Accelerate or Increase a Direct Financial Obligation Fortnsaf-8/28/2006
1710The stock has been doing very poorly -- down 60% this year -- because the compantnsaf-8/24/2006
1709Stock has been doing well, why no interest?Ivan Inkling-8/18/2006
1708Affymetrix Announces Update Regarding Stock Option Grants Wednesday August 9, 5:tnsaf-8/10/2006
1707Affymetrix Reports First Quarter 2006 Results Thursday April 20, 4:00 pm ET <tnsaf-4/21/2006
1706Device helps find fat gene SCIENTISTS USE SILICON VALLEY TOOL TO STUDY OBESITY sim1-4/14/2006
1705Perlegen Sciences files for $115 million IPO Mon Apr 10, 2006 6:43 AM ET WASHINnigel bates-4/10/2006
1704Certainly potential in the deals, but there is concern about the next generationtuck-2/21/2006
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):